Salix Pharmaceuticals (SLXP) is a pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract This stock is trading up 7.6% at $37.30 in recent trading.
Today's Volume: 1,044,000Average Volume: 949,841 Volume % Change: 165% This stock is spiking higher today after the company said it turned a profit in the third quarter on rising sales of its drug Xifaxan, used to treat diarrhea and certain neurological problems. Salix also agreed to buy privately held Oceana Therapeutics for $300 million in cash. From a technical standpoint, this stock has trigged a major breakout today now that shares have started to move above some near-term overhead resistance at $35.38. The next major resistance level that traders should watch is at $38.23. A high-volume move above $38.23 should set this stock up to ret-test its July high of $41.50. Ligand Pharmaceuticals Ligand Pharmaceuticals (LGND) is a biotechnology company that focuses on drug discovery and early-stage development of pharmaceuticals that address critical unmet medical needs. The stock is trading up 2.9% at $12.31 in recent trading Today's Volume: 204,000 Average Volume: 202,152 Volume % Change: 132% From a technical standpoint, this stock is starting to move higher today in the face of massive market declines on solid volume. Shares of LGND plunged on Tuesday from close to $16 to just under $12 a share on high volume. The stock has some previous support worth noting at $11.50, and after that big drop yesterday, shares never violated its 200-day moving average of $11.68. >>10 Most Shorted Stocks in Biotech Traders should put LGND on their radar for an oversold rebound play since the current relative strength index is showing a reading of 36, which is oversold. Look to use the 200-day as mental stop area in case the stock isn't done going down.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV